BeOne Reports New Phase 3 Survival Data for ZIIHERA
San Carlos, Calif. – August 31, 2026 BeOne Medicines announced new Phase 3 overall survival data from the HERIZON-GEA-01...
esophageal cancer
Advertisement
Jazz Pharmaceuticals Gains FDA Approval for HER2+ GEA
Dublin, Ireland, August 25, 2026 Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved two...
Aravax Wins FDA Fast Track Designation for PVX108
MELBOURNE, Australia & OXFORD, UK, Aug. 3, 2026 Aravax announced that the U.S. Food and Drug Administration (FDA) has...
IMPACT Therapeutics Names IMP3201 First Dual-Payload ADC Candidate
SHANGHAI, China, July 27, 2026 IMPACT Therapeutics announced the nomination of IMP3201 as a preclinical candidate (PCC), marking the...
Agilent Wins FDA Approval for PD-L1 22C3 Test
Santa Clara, USA – March 26, 2026 Agilent Technologies announced U.S. FDA approval of its PD-L1 IHC 22C3 pharmDx...
Advertisement
